Mylan Gets Industry Aid In $50M Tax Fight At 3rd Circ.

By Daniel Ducassi (August 9, 2022, 7:58 PM EDT) -- A generic-drug manufacturer trade group told the Third Circuit on Monday that taxing patent litigation costs related to the expedited approval process for generic drugs would undermine the purpose of the Hatch-Waxman Act that set up that process, driving up costs for consumers....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!